Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019).
Clarke, Noel W
De Bono, J
AffiliationUniversity of Warwick, Coventry, UK.
MetadataShow full item record
AbstractProstate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa-the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)-includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort.
CitationSurvival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). 2014: Eur Urol